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Abstract The aim of this study was to measure the serum
AMH (anti-Mullerian hormone) concentrations in a group
of boys with or without cryptorchidism, evaluation of
karyotypes, testicular position, morphology, and major
length of the undescended testes. Fifty boys who were
1–4 years old (median = 2.4 years) with unilateral crypt-
orchidism were evaluated. All of them underwent orchi-
dopexy in 2010. Prior to the procedure, all of the subjects
had undergone karyotyping to exclude chromosomal
abnormalities. Fifty healthy boys within the same age range
(median = 2.1 years) admitted for planned inguinal hernia
repair in 2010, served as controls. Blood samples were
collected, while obtaining blood for standard laboratory
tests routinely performed before the surgeries. Medians of
AMH in boys with cryptorchidism were lower than in boys
with inguinal hernia and differed signiﬁcantly between
two groups. Undescended testes were generally found in
superﬁcial inguinal pouch (n = 46), in two cases were
noted to be in the external ring of the inguinal canal, and in
another two instances, in the abdominal cavity. The major
lengths of the undescended testes were smaller in com-
parison to the testes positioned normally (mean of 1 cm vs.
a mean of 1.5 cm, respectively). In nine of the cases, the
testes had turgor deﬁcit, a drop shape, with epididymides
that were small, dysplastic, and separated from the testis.
The authors found that AMH was lower in boys with
unilateral cryptorchidism (also found to have smaller testis)
when compared with the control group.
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Introduction
The descend of testis from a temporary intra-abdominal
site in fetal life to the permanent scrotal location after birth
is crucial to spermatogenesis in mature testis. The etiology
of undescended testis is still surrounded by much contro-
versy. It is largely believed that disrupted endocrine reg-
ulation and several gene defects may play a role in the
process [1]. Nevertheless, the ﬁrst phase of typical testic-
ular descent takes place between the 10th and 15th week of
human gestation [2]. This occurrence is independent of
androgen levels, as the process has been found to transpire
in both animals and humans with complete androgen
insensitivity and may also be controlled by anti-Mullerian
hormone (AMH) and insulin-like hormone 3 (INSL3) [3–
5]. INSL3 is secreted by the Leydig cells shortly after the
onset of testicular development, and controls the thickening
of the gubernaculum anchoring the testis to the inguinal
region [6]. Disruption of the Insl3 gene in mice results in
bilateral intra-abdominal testes [7, 8]. In humans, on the
other hand, it was found that only 1.9% of the cases of
cryptorchidism were caused by INSL3 gene mutations, and
that the mutations of the INSL3 receptor on the whole,
were uncommon [9, 10]. This is in accordance with the fact
that intra-abdominal undescended testes comprise only 5%
of operations for undescended testes [11]. AMH, also
named Mullerian inhibiting substance, is a tissue-speciﬁc
TGF-beta superfamily growth factor. AMH is secreted by
immature Sertoli cells during the 8th week of gestation,
and is responsible for the regression of Mullerian ducts in
the male fetus as part of the sexual differentiation process
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DOI 10.1007/s12020-011-9551-5[12]. No extragonadal AMH source has been found thus
far. On the other hand, mutations in the gene for the ligand
or the AMH receptor cause the persistent Mullerian duct
syndrome in males, as well as the maldescent of the testis
[13]. Conversely, other studies have shown that AMH
receptor-deﬁcient mice undergo normal testis descent [14].
With the onset of puberty and spermatogenesis in
healthy men, the secretion of AMH declines corresponding
to the maturation of the Sertoli cells [15, 16]. The second,
or inguinoscrotal phase of testicular descent occurs
between 26th and 40th weeks of gestation [2]. During this
phase, the testis migrates through the inguinal canal and
across the pubic region to the scrotum. The testis and
epididymis then remain within the diverticulum of the
peritoneum, that elongates within the elongating guber-
naculum [17]. Furthermore, the gubernaculum growing out
of the abdominal wall might be under the control of Hox
genes—a group of genes that determines the basic structure
and orientation of an organism. Disruption of some Hox
genes in mice has been shown to lead to cryptorchidism,
but the relevance of this observation is debatable in human
studies of cryptorchidism [18]. There is much clinical
evidence on the other hand, that shows reduced androgen
action to be associated with undescended testes [19–21].
In this study, we measured the serum AMH concentra-
tions in a group of boys with or without cryptorchidism.
We evaluated karyotypes of these boys, as well as the
position, morphology, and major length of the undescended
testes.
Methods
Study population
Fifty boys aged 1–4 years (median = 2.4 years) with uni-
lateral cryptorchidism, and without previous human cho-
rionic gonadotropin treatment, were evaluated. All of them
underwent orchidopexy in 2010. An abnormal karyotype,
as well as the presence of any endocrine disorders, con-
stituted grounds for exclusion from the study. Prior to their
orchidopexy, all of the subjects had their karyotypes (to
exclude chromosomal abnormalities) and AMH serum
levels evaluated. During the actual orchidopexy, the posi-
tion and morphology of the testes were evaluated, and their
major length was measured.
Control group
Fifty healthy boys aged 1–4 years (median = 2.1 years)
admitted to the Pediatric Surgery Department for planned
inguinal hernia repairs in 2010, served as controls. All boys
in the control group had their testes in the scrotum. Their
karyotypes and AMH serum concentrations were also
determined prior to their procedures.
Blood samples were drawn from antecubital vein. Blood
was collected in tubes containing EDTA. The serum was
separated from cells by centrifugation. Serum samples were
made anonymous and stored at -20C, until the hormonal
analyses were performed. AMH was measured by a sensi-
tive immunoassay (Immunotech, Beckman Coulter Ltd.,
Marseilles, France (A11893)). Assay sensitivity indicated
by the manufacturer was 1 pM or 0.14 ng/ml and intra and
interassay coefﬁcients of variation (CV) were less than 12.3
and 14.2%, respectively. This immunoassay was a two-
immunological-step sandwich type assay.
Data was collected from patients admitted to Pediatric
Surgery Department for either a planned orchidopexy or
hernia repair, and blood samples were drawn while
obtaining blood for standard laboratory tests performed
prior to the scheduled surgeries. All parents of the patients
gave informed consent for both clinical and biochemical
follow-up.
The study was approved by the local Ethics Committee
as an audit of a clinically agreed-upon protocol of inves-
tigation and treatment.
The data is hereby shown as mean ± SD. Two-tail,
Mann–Whitney U test was used consistently throughout the
study. Correlations were analyzed using a Pearson test. The
P values less than 0.05 were considered signiﬁcant.
Results
There was no statistically signiﬁcant difference in the age
distribution of the two groups. All boys had karyotypes
46XY. Medians of AMH in boys with cryptorchidism
were lower than in boys with inguinal hernia, and differed
signiﬁcantly—74.8 and 95.6 ng/ml, respectively. The two-
tailed P value was 0.0042, and considered to be very sig-
niﬁcant. The 95% conﬁdence interval for cryptorchidism
was 67.9–86.5, while the 95% conﬁdence interval for the
inguinal hernia was 89.0 to 103.4. The standard error of
mean (SD) was 18.66 in cryptorchidism, and 19.66 in
inguinal hernia.
The undescended testes were generally found in the
superﬁcial inguinal pouch (n = 46), but in two of the
instances were located in the external ring of inguinal
canal, while two more subjects had theirs in the abdominal
cavity. The major lengths of the undescended testes dif-
fered from 0.8 to 2 cm, and in most cases these glands were
found to be smaller in comparison to the testes positioned
normally (mean 1 cm and mean 1.5 cm, respectively,
±0.3SD). They also correlated with lower AMH concen-
tration. In nine of the cases of cryptorchidism, the testes
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small, dysplastic, and separated from the testis.
Discussion
In healthy boys, there is a steep increase in circulating
AMH concentrations during the ﬁrst months of life. It is
followed by a decline to a stable level until the time of
puberty arrives, between Tanner stages II and III, where a
renewed decline to another stable level through adoles-
cence and adulthood is found [16]. Bearing in mind the
aforementioned fact, we studied the population of boys
with and without cryptorchidism, who were between 1 and
4 years old (Tanner stage I).
Serum AMH is known to be valuable in the evaluation
of bilateral cryptorchidism and furthermore in assessing
gonadal function [22, 23]. A measurable value in a boy
with bilateral cryptorchidism is predictive of undescended
testes, while an undetectable value is highly suggestive of
anorchia [24]. Only Sertoli cells remain active during
childhood, so the evaluation of gonadal function in the
prepubertal male relies on the assessment of Sertoli cell
products [15, 25–27].
Unilateral cryptorchidism carries an increased risk of
infertility in adulthood. Up to 30% of men operated on in
childhood for unilateral cryptorchidism are likely to be
subfertile in later life [28–31]. Men who undergo an
operation for bilateral cryptorchidism are more affected—
up to 54% are infertile according to their semen and hor-
monal analysis [29, 32]. The position of the testes at the
time of orchidopexy is also important. In fact, a lack of
fertility has been reported in men who underwent bilateral
abdominal orchidopexy in childhood [33]. Even though we
evaluated boys with unilateral cryptorchidism, whose testes
were positioned in most cases in inguinal pouch, the
median serum AMH—a Sertoli cell marker evaluating
gonadal function—was lower than in boys with both testes
in the scrotum. According to Lukas-Croisier et al. [34] low
serum AMH correlates with small testes. In our study,
mean diameters of undescended testes were smaller in
comparison to the normally developing ones (1 9 0.5 and
1.5 9 0.8 cm, respectively).
Testicular size and sperm density are positively corre-
lated to germ-cell status in the cryptorchid testes in child-
hood [28, 35]. Lower serum AMH concentrations in
otherwise healthy boys with cryptorchidism, who were
compared with their age-matched counterparts with palpa-
ble testes, have also been reported in two pervious studies
[36, 37]. In contrast, Aksglaede et al. [38] did not ﬁnd the
difference in AMH concentrations between patients with
Klinefelter Syndrome, with or without a history of cryptor-
chidism. The exception to this was noted in untreated
patients, 10–14 years old, in whom the expected puberty
decline in AMH tended to occur later than in the non-
cryptorchid patients of the same age. Some authors argue
that the negative correlation between testosterone and AMH
suggests that androgens are responsible for AMH down-
regulation [23]. The coexistence of high levels of androgens
and AMH during fetal life and the ﬁrst months after birth is
thereby explained by the androgen insensitivity of Sertoli
cells during this period, due to the lack of androgen receptor
expression [39–42].
Conclusions
We found that serum AMH concentration—a Sertoli cell
marker evaluating gonadal function—is lower in boys with
cryptorchidism operated upon between the 1st and 4th year
of life. This reﬂection of a Sertoli cell defect may subse-
quently be primary or secondary to testicular descent
failure.
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